Physician profile
Mark L Moster
NPI 1376511980
$53,151.85
in general payments reported to CMS, 2019-2025
31 companies · $724 in 2025
The $724 reported for 2025 was more than what 75% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $8,296 · 2021: $18K · 2022: $3,901 · 2023: $1,979 · 2024: $3,620 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,563 · Consulting Fee: $2,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,562.58 |
| Consulting Fee | $2,760.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34,078.76 | 2019-2022 | |
| Horizon Therapeutics Plc | $8,621.87 | 2019-2023 | Uplizna, Tepezza |
| Amgen INC. | $3,162.54 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $1,083.84 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Glaukos Corporation | $1,044.53 | 2019-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $757.88 | 2022-2025 | Rocklatan, Hydrus Microstent |
| Biogen, INC. | $616.00 | 2019-2023 | Vumerity |
| Novartis Pharmaceuticals Corporation | $533.60 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $499.22 | 2019-2021 | |
| Sight Sciences, INC. | $367.81 | 2019-2024 | Omni Surgical System, Sion Surgical Instrument |
| Genentech USA, INC. | $346.58 | 2019-2023 | Enspryng |
| Allergan, INC. | $332.05 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $299.65 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $229.56 | 2019 | |
| New World Medical,INC. | $197.29 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $154.08 | 2020-2022 | |
| Argenx US, INC. | $148.70 | 2022-2023 | Vyvgart |
| Ivantis, INC | $124.80 | 2020 | |
| Abbvie INC. | $124.48 | 2024 | |
| W. L. Gore & Associates, INC. | $79.37 | 2023-2024 | Product In Development |
| Janssen Pharmaceuticals, INC | $69.17 | 2022-2023 | Ponvory |
| Merz Pharmaceuticals, LLC | $65.44 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $44.10 | 2020-2021 | |
| Thea Pharma INC. | $42.41 | 2024 | Iyuzeh |
| Emd Serono, INC. | $34.90 | 2022 | |
| Merz North America, INC. | $23.06 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Celgene Corporation | $19.34 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $15.90 | 2022 | |
| Tg Therapeutics, INC. | $15.52 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$157,590.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Moster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.